title: Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab.
abstract: Increase in radiopharmaceutical uptake is an indicator of progression of disease. Paradoxical increase in the radiopharmaceutical uptake also occurs during favorable response to therapy, which is designated as flare phenomenon. Flare phenomenon is well documented on bone scinitgraphy when initially noted lesions show increased radiotracer uptake after therapy is instituted. This happens despite favorable response to the treatment. The osteoblastic activity associated with healing response of bone tumors is the cause of flare phenomenon. Recently, metabolic flare phenomenon has been described in patients with breast cancer who undergo hormonal therapy. Changes in the hormonal level during initial part of the treatment is the cause of metabolic flare. We describe a patient with bilateral breast cancer who underwent second line chemotherapy along with bevacizumab. Serial positron emission tomography scans done showed interesting phenomenon of metabolic flare.
authors.affiliation: Department of Nuclear Medicine and PET-CT, Amala Institute of Medical Sciences, Amala Nagar, Thrissur, Kerala, India.
authors.forename: Chidambaram Natrajan
authors.initials: CN
authors.lastname: Balasubramanian Harisankar
authors.affiliation: Department of Radiodiagnosis, Amala Institute of Medical Sciences, Amala Nagar, Thrissur, Kerala, India.
authors.forename: Rajalakshmi
authors.initials: R
authors.lastname: Preethi
authors.affiliation: Department of Radiodiagnosis, Amala Institute of Medical Sciences, Amala Nagar, Thrissur, Kerala, India.
authors.forename: Jijoe
authors.initials: J
authors.lastname: John
keywords: Breast cancer; fluorodeoxy glucose positron emission tomography; metabolic flare; response assessment
references.citation: Eur J Radiol. 2014 Oct;83(10 ):1925-33
references.pmid: 24985086
references.citation: Br J Cancer. 2009 Oct 20;101(8):1225-32
references.pmid: 19789531
references.citation: Semin Nucl Med. 2001 Jul;31(3):206-11
references.pmid: 11430527
references.citation: J Clin Oncol. 2001 Jun 1;19(11):2797-803
references.pmid: 11387350
references.citation: AJR Am J Roentgenol. 2006 Jun;186(6):1783-6
references.pmid: 16714674
references.citation: J Thorac Oncol. 2009 Mar;4(3):429-31
references.pmid: 19247091
references.citation: Clin Breast Cancer. 2013 Aug;13(4):271-9
references.pmid: 23714689
references.citation: Tohoku J Exp Med. 2012;228(2):163-8
references.pmid: 23036980
references.citation: Indian J Nucl Med. 2014 Jan;29(1):34-7
references.pmid: 24591781